Abstract | PURPOSE: METHODS: Patients with high-risk stage II, III, or IV breast cancer were randomized to receive lipegfilgrastim 6 mg (n = 101) or pegfilgrastim 6 mg (n = 101) subcutaneously on day 2 of each CTx cycle. Doxorubicin 60 mg/m(2) plus docetaxel 75 mg/m(2) commenced on day 1, for up to four cycles. Secondary end points included days in the hospital or intensive care unit (ICU), use of intravenous antibiotics for febrile neutropenia (FN) or related infections, and measures of CTx delivery (dose delays, reductions, and omissions). RESULTS: CONCLUSIONS:
|
Authors | Oleg A Gladkov, Anton Buchner, Peter Bias, Udo Müller, Reiner Elsässer |
Journal | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
(Support Care Cancer)
Vol. 24
Issue 1
Pg. 395-400
(Jan 2016)
ISSN: 1433-7339 [Electronic] Germany |
PMID | 26092233
(Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Recombinant Proteins
- Taxoids
- Granulocyte Colony-Stimulating Factor
- Docetaxel
- pegfilgrastim
- Polyethylene Glycols
- Doxorubicin
- Filgrastim
|
Topics |
- Administration, Cutaneous
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects)
- Breast Neoplasms
(drug therapy)
- Chemotherapy-Induced Febrile Neutropenia
(etiology)
- Cost of Illness
- Critical Care
(statistics & numerical data)
- Docetaxel
- Doxorubicin
(administration & dosage, adverse effects)
- Female
- Filgrastim
- Granulocyte Colony-Stimulating Factor
(administration & dosage, adverse effects)
- Humans
- Length of Stay
(statistics & numerical data)
- Middle Aged
- Polyethylene Glycols
- Recombinant Proteins
(administration & dosage, adverse effects)
- Risk Factors
- Taxoids
(administration & dosage, adverse effects)
|